Haemodynamic and ventilatory support in severe sepsis

Journal of the Royal College of Physicians of London

Volumn 34, Issue 6, 2000, Pages 522-528

  Callister, Matthew E J ^b   Evans, Timothy W ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b Royal Brompton Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

STEROID; VASOCONSTRICTOR AGENT;

ARTIFICIAL VENTILATION; BODY POSTURE; FLUID THERAPY; HEMODYNAMICS; HUMAN; HYPOTENSION; LUNG DISEASE; MICROBIOLOGY; PROGNOSIS; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

FLUID THERAPY; HEMODYNAMIC PROCESSES; HUMANS; HYPOTENSION; LUNG DISEASES; POSTURE; PROGNOSIS; RESPIRATION, ARTIFICIAL; SEPSIS; SHOCK, SEPTIC; STEROIDS; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 0034331829     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101: 1644-55.
2. Green J, Lynn WA. Presentation and clinical features of severe sepsis. J R Coll Physicians Lond 2000;34:418-23.
3. Hebert PC, Drummond AJ, Singer J, Bernard GR, Russell JA. A simple multiple system organ failure scoring system predicts mortality of patients who have sepsis syndrome. Chest 1993;104:230-5.
4. Noursadeghi M, Cohen J. Immunopathogenesis of severe sepsis. J R Coll Physicians Lond 2000;34:432-6.
5. Singh S, Wort SJ, Evans TW. Inducible nitric oxide and pulmonary infection. Thorax 1999;54:959-60.
6. Grover R, Zaccardelli D, Colice G, Guntupalli K, et al. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl-L-arginine hydrochloride (546C88), in patients with septic shock. Crit Care Med 1999;27: 913-22.
7. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 1994;154:2484-91.
8. Bone RC, Balk RA, Fein AM, Perl TM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23:994-1006.
9. Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733-42.
10. Abraham E, Wunderink R, Silverman H, Perl TM, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934-41.
11. Fein AM, Bernard GR, Criner GJ, Fletcher EC, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 1997;277:482-7.
12. Wasserman D, Ioannovich JD, Hinzmann RD, Deichsel G, et al. Interferon-gamma in the prevention of severe burn-related infections: a European phase III multicenter trial. The Severe Burns Study Group. Crit Care Med 1998;26:434-9.
13. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase II, randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 1997;25: 1115-24.
14. Dhainaut JF, Tenaillon A, Le-Tulzo Y, Schlemmer B, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994;22: 1720-8.
15. Heard SO, Fink MP, Gamelli RL, Solomkin JS, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit Care Med 1998;26:748-54.
16. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med 1996;334: 1697-702.
17. Abraham E, Glauser MP, Butler T, Garbino J, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. RO 45-2081 Study Group. JAMA 1997;277:1531-8.
18. Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207-14.
19. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-9.
20. Wyncoll DLA, Evans TW. Acute respiratory distress syndrome. Lancet 1999;354: 497-501.
21. Antonelli M, Conti G, Rocco M, Bufi M, et al. A comparison of non-invasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998;339:429-35.
22. Amato MBP, Barbas CSV, Medeiros DM, Magaldi RB, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. N Engl J Med 1998;338:347-54.
23. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-8.
24. Chatte G, Sab JM, Dubois JM, Sirodot M, et al. Prone position in mechanically ventilated patients with severe acute respiratory failure. Am J Respir Crit Care Med 1997;155:473-8.
25. Nakos G, Tsangaris I, Kostanti E, Nathanail C, et al. Effect of the prone position on patients with hydrostatic pulmonary edema compared with patients with acute respiratory distress syndrome and pulmonary fibrosis. Am J Respir Crit Care Med 2000;161:360-8.
26. Choi PT, Yip G, Quinonez LG, Cook DJ. Crystalloids vs colloids in fluid resuscitation: a systematic review. Crit Care Med 1999;27:200-10.
27. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. Br Med J 1998;316:961-4.
28. Humphrey H, Hall J, Sznajder I, Silverstein M, Wood L. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure. Chest 1990;97:1176-80.
29. Mitchell JP, Schuller D, Calandrino FS, Schuster DP. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis 1992;145:990-8.
30. Meadows D, Edwards JD, Wilkins RG, Nightingale P. Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 1988;16:663-6.
31. Meier-Hellmann A, Reinhart K, Bredle DL, Specht M, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997;25:399-404.
32. Levy B, Bollaert PE, Charpentier C, Nace L, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism and gastric tonometric variables in septic shock: a prospective, randomised study. Intensive Care Med 1997;23:282-7.
33. Day NPJ, Phu NH, Bethell DP, Mai NTH, et al. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet 1996;348:219-23.
34. James JH, Luchette FA, McCarter FD, Fischer JE. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999;354:505-8.
35. Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994;272:1354-7.
36. Connors AF Jr, Speroff T, Dawson NV, Thomas C, et al. The effectiveness of right heart catheterization in the initial care of critically ill patients. JAMA 1996;18: 889-97.
37. Pulmonary artery catheter consensus conference: consensus statement. Crit Care Med 1997;25:910-25.
38. Hayes MA, Timmins AC, Yau EHS, Palazzo M, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994;330:1717-22.
39. Gattinoni L, Brazzi L, Pelosi P, Latini R, et al. A trial of goal-orientated hemodynamic therapy in critically ill patients. N Engl J Med 1995;333:1025-32.
40. Lefering R, Neugebauer EAM. Steroid controversy in septic shock: a meta-analysis. Crit Care Med 1995;23: 1294-303.
41. Bollaert PE, Charpentier C, Levy B, Debouverie M, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645-50.
42. Briegel J, Forst H, Haller M, Schelling G, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomised, double-blind, single-centre study. Crit Care Med 1999;27: 723-32.
43. Meduri GU, Headley AS, Golden E, Carson SJ, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome. JAMA 1998;280:159-65.
44. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomised phase II trial. Crit Care Med 1998;26:15-23.
45. Walmrath D, Schneider T, Schermuly R, Olschewski H, et al. Direct comparison of inhaled nitric oxide and aerosolised prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153:991-6.